Veterinary Medicine Advisory Committee
The Secretary and, by delegation, the Assistant Secretary for the Office of Public Health and Science and the Commissioner of Food and Drugs are charged with the administration of the Federal Food, Drug, and Cosmetic Act, the Fair Packaging and Labeling Act, and various provisions of the Public Health Service Act. The Veterinary Medicine Advisory Committee advises the Commissioner or designee in discharging responsibilities as they relate to assuring safe and effective drugs, feeds and feed additives, and devices for animal use, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility.
15 U.S.C. 1451 et seq.; 21 U.S.C. 321, 341, 342, 343, 343-1, 344, 345, 346, 348, 349, 350, 350a, 351, 352, 353(f), 355, 360b, 360c-j, 371, 375, 376, 378, 379e, 381, 393, 394, 881(b); 42 U.S.C. 217a, 241, 242, 242a, 262, 264: 21 CFR Part 14, 330.10(a); the Committee is governed by the provisions of Public Law 92-463, as amended (5 U.S.C. App. 2), which sets forth standards for the formation and use of advisory committees.
The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational new animal drugs, feeds, and devices for use in the treatment and prevention of animal diseases and increased animal production, and makes appropriate recommendations to the Commissioner of Food and Drugs regarding scientific issues and regulatory policies.
The Committee will consist of a core of 13 voting members including the Chair. Members and the Chair are selected by the Commissioner, or designee, from among authorities knowledgeable in the fields of companion animal medicine, food animal medicine, avian medicine, microbiology, biometrics, toxicology, pathology, pharmacology, animal science, chemistry, public health/epidemiology and minor species/minor use veterinary medicine. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting member who is identified with industry interests.
The Commissioner or designee shall have the authority to select members of other scientific and technical FDA Advisory Committees (normally not to exceed 10 members) to serve temporarily as voting members and to designate consultants to serve temporarily as voting members when: (1) expertise is required that is not available among current voting standing members of the Committee (when additional voting members are added to the Committee to provide needed expertise, a quorum will be based on the combined total of regular and added members), or (2) to comprise a quorum when, because of unforeseen circumstances, a quorum is or will be lacking.
If functioning as a medical device panel, a nonvoting representative of consumer interests and a nonvoting representative of industry interests will be included in addition to the voting members.
Members shall be invited to serve for overlapping terms of four years. Terms of more than two years are contingent upon the renewal of the Committee by appropriate action prior to its expiration.
Temporary subcommittees consisting of two or more Committee members may be established by the Commissioner or designee as needed to address specific issues within their respective areas of expertise.
Subcommittees shall make preliminary recommendations regarding specific issues for subsequent action by the full Committee. The Department Committee Management Officer shall be notified upon establishment of each subcommittee, and shall be provided information on its name, membership, function, and estimated frequency of meetings.
Management and support services shall be provided by the Office of the Director, Center for Veterinary Medicine, Food and Drug Administration.
Meetings shall be held approximately twice a year at the call of the Designated Federal officer, who also shall approve the agenda. A Designated Federal officer shall be present at all the meetings.
Because of the size of the Committee and the variety in the types of issues that it will consider, FDA may, in connection with a particular committee meeting, specify a quorum that is less than a majority of the current voting members. The Agency’s regulations (21 CFR 14.22(d)) authorize a committee charter to specify quorum requirements.
Meetings shall be open to the public except as may be determined otherwise by the Commissioner or designee in accordance with the Government in the Sunshine Act (5 U.S.C. 552b(c)) and the Federal Advisory Committee Act. Notice of all meetings shall be given to the public.
Meetings shall be conducted and records of the proceedings kept as required by applicable laws and Departmental regulations.
Members who are not full-time Federal employees shall be paid at the rate of the General Schedule 15, step 10, per day for time spent at meetings, plus per diem and travel expenses in accordance with Standard Government Travel Regulations.
Annual Cost Estimate
The estimated annual cost for operating the Committee, including compensation and travel expenses for members but excluding staff support, is $47,084.00. The estimated person-years of staff support required is .3 at an estimated annual cost of $48,976.00.
In the event that the Commissioner or designee determines that a portion of a meeting is closed to the public in accordance with the Government in the Sunshine Act ( 5 U.S.C. 552b(c)) and the Federal Advisory Committee Act, a report shall be prepared not later than November 1 of each year which contains as a minimum the function of the Committee, a list of members and their business addresses, the dates and place of meetings, and a summary of the Committee’s activities and recommendations during the preceding year. A copy of the report shall be provided to the Department Committee Management Officer.
Unless renewed by appropriate action prior to its expiration, the Veterinary Medicine Advisory Committee will terminate on April 24, 2010.
Date Randall W. Lutter, Ph.D.
Deputy Commissioner for Policy, FDA